Faeth Therapeutics expands board, adds co-founder Karen Vousden

Faeth Therapeutics disclosed in a Form 8-K that on September 11, 2026, its Board of Directors expanded from five to six seats and named Karen Vousden, Ph.D. as a new Class II director, with the appointment taking effect immediately.¹ Her term is set to run until the company's 2029 annual meeting of stockholders, or until a successor is elected or she leaves the board earlier through death, resignation, or removal.¹ She was also named to the Board's Compensation Committee, effective immediately.¹

Dr. Vousden, age 68, is described as a cancer biologist known for her research into the p53 tumor suppressor protein's regulation and function.¹ She holds a direct tie to the company, having co-founded Faeth in April 2019.¹ Her other current post is Principal Group Leader at The Francis Crick Institute, a role she has held since February 2017.¹ Earlier in her career, she was Chief Scientist of Cancer Research UK from 2016 to 2022 and led the Beatson Institute of Cancer Research as director from 2002 to 2016.¹ She also brings public-company board experience, having served on Bristol Myers Squibb's board since 2018, where she sits on its Science and Technology Committee and its Compensation and Management Development Committee.¹

Under Faeth's director pay program, Dr. Vousden's initial equity award is an option to buy 25,000 shares of common stock, priced at the closing share price on the grant date.¹ The filing states these options vest in equal monthly installments over three years from the grant date, contingent on continued service, and vest fully if a change in control occurs.¹ The company also confirmed no family ties link her to existing officers or directors, and no arrangements existed with any other party regarding her appointment.¹